Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | P4HB | P07237 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA6 | P23280 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 4/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6313757 | 1.00 | SLC22A12 (0.38) | SLC22A12AURKBP4HBPKMCA12 | |
| SCHEMBL7077622 | 1.00 | SLC22A12 (0.38) | SLC22A12AURKBP4HBPKMCA12 | |
| SCHEMBL6306954 | 0.84 | CA12 (0.42) | SLC22A12AURKBP4HBPKMCA12 | |
| SCHEMBL6306969 | 0.84 | CA12 (0.42) | SLC22A12AURKBP4HBPKMCA12 | |
| SCHEMBL7078673 | 0.84 | GLA (0.39) | SLC22A12AURKBP4HBPKMCA12 | |
| SCHEMBL6309422 | 0.84 | GLA (0.39) | SLC22A12AURKBP4HBPKMCA12 | |
| SCHEMBL6309125 | 0.84 | GLA (0.39) | SLC22A12AURKBP4HBPKMCA12 | |
| SCHEMBL6307825 | 0.83 | TSHR (0.36) | LMNAKMT2AMAPTMEN1GAA | |
| SCHEMBL6312743 | 0.83 | TSHR (0.36) | LMNAKMT2AMAPTMEN1GAA | |
| SCHEMBL6307228 | 0.82 | LMNA (0.48) | LMNAKMT2AMAPTMEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1489596-A | Alpha-substituted beta-aminoethylphosphonates | �Ʒ� | 2004-04-14 | — | — | CN | claimed |
| EP-1320536-A1 | $g(a)-SUBSTITUTED $g(b)-AMINOETHYL PHOSPHONATES | Ilex Oncology Research S.A. (CH) | 2003-06-25 | — | — | EP | claimed |
| US-20020111332-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | ILEX PRODUCTS, INC. | 2002-08-15 | — | — | US | claimed |
| WO-2002026752-A1 | α-SUBSTITUTED β-AMINOETHYL PHOSPHONATES | ILEX ONCOLOGY RESEARCH S.A. (CH) | 2002-04-04 | — | — | WO | claimed |
| US-20050187193-A1 | Reducing plasma levels of apo B and LDL cholesterol and in decreasing plasma total cholesterol; restenosis following angioplasty; atherosclerosis, hypercholesterolemia; use with other drugs such as statins; e.g. diethyl alpha-(3,5-dimethoxy-4-hydroxyphenyl)-beta-(N-(3-pyridyl)-amino)-vinylphosphonate | ILEX PRODUCTS, INC. | 2005-08-25 | — | — | US | disclosed |
| CN-1489596-A | Alpha-substituted beta-aminoethylphosphonates | �Ʒ� | 2004-04-14 | — | — | CN | disclosed |
| US-6706698-B2 | ANTICHOLESTEROL AGENTS | ILEX PRODUCTS, INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1320536-A1 | $g(a)-SUBSTITUTED $g(b)-AMINOETHYL PHOSPHONATES | Ilex Oncology Research S.A. (CH) | 2003-06-25 | — | — | EP | disclosed |
| US-20030114421-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | PHAN HIEU TRUNG (CH) | 2003-06-19 | — | — | US | disclosed |
| US-20020111332-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | ILEX PRODUCTS, INC. | 2002-08-15 | — | — | US | disclosed |
| WO-2002026752-A1 | α-SUBSTITUTED β-AMINOETHYL PHOSPHONATES | ILEX ONCOLOGY RESEARCH S.A. (CH) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114421-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | APOB, PHOSPHO1, APOL1 | SLC22A12 1516/4885AURKB 1350/4885P4HB 1728/4885 |
| US-20020111332-A1 | Alpha-substituted beta-aminoethyl phosphonate derivatives | APOB, PHOSPHO1, APOL1 | SLC22A12 1516/4885AURKB 1350/4885P4HB 1728/4885 |
| US-20050187193-A1 | Reducing plasma levels of apo B and LDL cholesterol and in decreasing plasma total cholesterol; restenosis following angioplasty; atherosclerosis, hypercholesterolemia; use with other drugs such as statins; e.g. diethyl alpha-(3,5-dimethoxy-4-hydroxyphenyl)-beta-(N-(3-pyridyl)-amino)-vinylphosphonate | APOB, LDLR, HDLBP | SLC22A12 2652/4885AURKB 1205/4885P4HB 375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.